Management of hairy cell leukemia variant

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 2, 2011, Pages 53-56

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

cladribine; Hairy cell leukemia variant; immunotoxins; pentostatin; purine nucleoside analogs; rituximab

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CLADRIBINE; IMMUNOTOXIN; IMMUNOTOXIN BL22; MOXETUMOMAB PASUDOTOX; PENTOSTATIN; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; CONTINUOUS INFUSION; DISEASE COURSE; HAIRY CELL LEUKEMIA; HAIRY CELL LEUKEMIA VARIANT; PRIORITY JOURNAL; REMISSION; SPLENECTOMY; SURVIVAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; LEUKEMIA, HAIRY CELL; TREATMENT OUTCOME;

EID: 79957459108     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.566392     Document Type: Article

References (14)

1. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16:41-56.
2. Piris M, Foucar K, Mollejo M, Campo E, Falini B. Splenic Bcell lymphoma/leukemia unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp 191-192.
3. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001;15:184-186. (Pubitemid 32124084)
4. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365-376. (Pubitemid 44087867)
5. Sainati L, Matutes E, Mulligan S, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990;76: 157-162. (Pubitemid 20220805)
6. Robak T, Błasińska-Morawiec M, Błoń ski J, et al. 2- Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999;62:49-56. (Pubitemid 29029918)
7. Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica 2002;87:107-108. (Pubitemid 34101120)
8. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011; 37:3-10.
9. Sasaki M, Sugimoto K, Mori T, Karasawa K, Oshimi K. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol 2008;119:48-53. (Pubitemid 351363859)
10. Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 2005;90(Suppl.):ECR26.
11. Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005;46:1229-1232. (Pubitemid 41087031)
12. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23:1-13.
13. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- resistant hairy-cell leukemia. N Engl J Med 2001;345: 241-247. (Pubitemid 32695063)
14. Kreitman RJ, Tallman MS, Coutre SE, et al. Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia. J Clin Oncol 2010;28(15 Suppl.): Abstract 6523.